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Abstract
Noninvasive prenatal diagnosis of chromosomal
aneuploidies, although challenging, has been achieved
through the implementation of novel methodologies
such as methylated DNA immunoprecipitation and next
generation sequencing technologies. Nevertheless,
additional developments are required towards the
interpretation of other fetal abnormalities of higher
complexity, such as de novo mutations including
microdeletion and microduplication syndromes as well
as complex diseases. The application of next generation
sequencing technologies towards fetal whole genome
recovery has demonstrated great potential to achieve
the above goal. In a research article published in
Genome Medicine, Chen et al. presented a novel
approach that allowed more robust and accurate
characterization of parental alleles compared with
previous studies. This was achieved through a
revolutionary strategy based on the use of trios and
unrelated individuals that simultaneously targets the
interpretation of the fetal haplotype and phenotype in
one step. It is hereby shown that the implementation of
a more accurate experimental design in combination
with proper analytical tools can provide robust
noninvasive fetal whole genome recovery with the
potential for further developments beyond the DNA
level.
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Introduction
The implementation of noninvasive prenatal diagnosis
(NIPD) for chromosomal aneuploidies has been one of
the most fascinating achievements for the scientific
world because it can offer a safer diagnosis for the fetus
after just 10 weeks of gestation [1-7]. Although the chal-
lenges associated with the development of NIPD for
common aneuploidies have been overcome, the field of
NIPD lies beyond the need for prenatal diagnosis of
common aneuploidies. Further expansion is required
towards the exploitation and diagnosis of other fetal
abnormalities that are subtle, infrequent and are not
restricted to copy number changes. The implementation
of next generation sequencing technologies in the devel-
opment of NIPD has revolutionized the field and has
provided new insight towards further expansion of
NIPD. In 2010, the possibility of using next generation
sequencing technologies towards whole genome fetal
recovery was described for the first time [8]. More
recent studies have supported the initial finding, provid-
ing new perspectives in the field of NIPD [9,10].
In a research article published in Genome Medicine,
Chen et al. presented a novel approach to NIPD that
allowed more robust and accurate characterization of
parental alleles compared with previous studies [11]. We
here aim to address the advantages of the methodology
applied by Chen et al. compared with previously devel-
oped methodologies towards noninvasive whole genome
fetal recovery. Furthermore, we discuss the potential for
future developments of the approach proposed by Chen
et al.
Noninvasive prenatal diagnosis for screening fetal
abnormalities
The need for further developments towards prenatal
diagnosis of other fetal abnormalities, including Mende-
lian diseases as well as complex diseases, has led to the
development of technologies towards noninvasive fetal
whole genome recovery. The application of next
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generation massively parallel sequencing has shown to
be a very promising approach that would allow exten-
sive investigation of the fetal genome [8-10]. Neverthe-
less, the approaches described so far are not free of
limitations and challenges, and require further investiga-
tion and improvement. Chen et al. introduced a novel
approach towards noninvasive whole genome fetal
recovery that overcomes a large number of limitations
associated with previously developed methodologies.
Previous studies have focused on inferring the fetal
genotype based on a maternal haplotype-assisted
approach with no additional interest in the characteriza-
tion of the biparental heterozygous sites in the fetal gen-
ome. As a consequence, there is an uncertainty regarding
the accuracy of paternal allele recovery. Chen et al. intro-
duced a novel approach for fetal genome recovery that
takes into account the paternal allele transition in mater-
nal plasma [11]. This strategy has allowed the assessment
of both fetal genotype and fetal phenotype simulta-
neously and in one step. They used, for the first time, a
combined strategy of trios and unrelated individuals to
construct parental haplotypes. This allowed a more
robust investigation of the fetal genome compared with
previous studies that have used only trios [9,10].
Although previous studies have achieved accurate
whole genome fetal recovery, their technology is
restricted by the limited cell-free fetal DNA (cffDNA)
concentration present in maternal plasma, which allowed
only the assessment of cases that had a cffDNA concen-
tration >6% [10]. One of the most important characteris-
tics of the strategy developed by Chen et al. is that it
allows the reconstruction of the fetal genome irrespective
of the cffDNA concentration and sequence depth. This
strategy led to 100% maternal and paternal allele recovery
in contrast to previous methodologies, which were only
able to achieve a recovery rate >91.4% for maternal and
71.60% to 72.94% for paternal alleles [9,10]. This is the
first time that such a high recovery rate has been
achieved, demonstrating the importance and the need for
a combined genotype-haplotype approach, as the haplo-
type information is essential for complex diseases screen-
ing and identification of fetal de novo copy number
variations, including microdeletion and microduplication
syndromes.
Analysis pipeline
It is of great interest to evaluate the analysis pipeline
applied by Chen et al. compared with that applied by
other groups. Previous studies have implemented a site-
by-site strategy to determine the paternal-specific allele
[10], occasionally in combination with population-scale
sequencing data [9]. However, the above approaches
retrieved only 60.3% to 70% of paternal-specific alleles.
These results impose the inaccuracy of using only a site-
by-site strategy approach in minute amounts of cffDNA
and in low sequencing read depth.
Chen et al. have revolutionized the field by introducing a
new strategy in which a combination of analytical tools
were applied to reveal both the haplotype and genotype of
the fetus, in contrast to previous studies that focus on the
fetal genotype inference [11]. Fetal haplotype recovery was
achieved by using the parental haplotypes obtained by the
genetic analysis software BEAGLE (a software package for
analysis of large-scale genetic data sets with hundreds of
thousands of markers genotyped on thousands of samples)
for both parental genotype and grandparents’ genotyping
data in combination with data obtained from the trio
study of the Han Chinese 1000 Genomes Project (pilot II)
[12]. They managed to achieve fetal whole genome recov-
ery in one step, with 100% recovery of the paternal allele
and characterization of recombination breakpoints, by
using the site-by-site strategy approach along with the
Hidden Markov Mode and Viterbi algorithm.
Future directions and conclusions
The strategy developed by Chen et al. aimed to recover
both fetal haplotype and genotype in one step. They
used, for the first time, trios in combination with unre-
lated individuals and achieved a more accurate character-
ization of parental haplotypes, reaching a predicted rate
of 100%. It is clear that this novel approach will facilitate
a broader scope in the field of NIPD, including the char-
acterization of Mendelian diseases, the screening of com-
plex diseases and the identification of de novo copy
number changes, including microdeletion and microdu-
plication syndromes. Although further developments are
still required for more accurate fetal de novo mutation
detection, the Chen et al. study has demonstrated the
dynamics associated with the use of three generations of
a family, which can potentially lead to the more robust
identification of both rare and common mutations in the
fetal genome.
Moreover, this study demonstrated an increase in accu-
racy, especially for paternal allele recovery, even in cases
with a limited amount of cffDNA (>6%) and at lower
sequence depth. This information is of great importance
because the technology will not be limited to early gesta-
tion, in contrast to previously developed methodologies.
Accurate and robust noninvasive fetal whole genome
recovery will also offer solutions at different levels, such as
the DNA level (for example, microdeletions, microduplica-
tions and point mutations), the level of epigenetic modifi-
cations (for example, methylation and chromatin) as well
as the translational level (for example, mRNA and micro-
RNAs). Nevertheless, further experimental designs and
analytical tool developments are required to decipher such
complex information.
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Although the current cost for next generation sequen-
cing - especially at the magnitude of whole genome recov-
ery, - is restrictive, it is expected that further technology
developments will reduce the cost and will provide more
applicable approaches with short turnaround times for
noninvasive fetal whole genome recovery.
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